ストックスクリーナーアプリを入手
270.67
2.17%
5.74
前日終値:
$264.93
開ける：
$264.28
24時間の取引高:
341.91K
Relative Volume:
1.57
時価総額：
$7.31B
収益：
$2.58B
当期純損益:
$-778.69M
株価収益率:
-9.9038
EPS:
-27.33
ネットキャッシュフロー:
$223.75M
1週間 パフォーマンス:
-7.84%
1か月 パフォーマンス:
-13.67%
6か月 パフォーマンス:
-4.91%
1年 パフォーマンス:
-4.43%
1日の値動き範囲:
$263.51
$271.84
1週間の範囲:
$251.00
$296.34
52週間の値動き範囲:
$211.43
$343.12
Bio Rad Laboratories Inc Stock (BIO) Company Profile
名前
Bio Rad Laboratories Inc
セクター
電話
(510) 724-7000
住所
1000 ALFRED NOBEL DRIVE, HERCULES
Compare BIO vs ABT, SYK, MDT, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BIO
Bio Rad Laboratories Inc
|
270.67 | 7.15B | 2.58B | -778.69M | 223.75M | -27.33 |
|
ABT
Abbott Laboratories
|
113.29 | 195.21B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
SYK
Stryker Corp
|
377.32 | 141.28B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
98.49 | 123.60B | 35.48B | 4.64B | 5.41B | 3.5856 |
|
BSX
Boston Scientific Corp
|
76.28 | 113.14B | 20.08B | 2.89B | 3.82B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
78.98 | 45.52B | 6.07B | 1.06B | 799.60M | 1.8527 |
Bio Rad Laboratories Inc Stock (BIO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-10-01 | アップグレード | Citigroup | Neutral → Buy |
| 2024-08-28 | 開始されました | Wells Fargo | Equal Weight |
| 2024-06-03 | 再開されました | Jefferies | Hold |
| 2024-04-03 | ダウングレード | Citigroup | Buy → Neutral |
| 2023-12-07 | 開始されました | UBS | Buy |
| 2023-06-16 | 開始されました | Wells Fargo | Overweight |
| 2022-12-07 | 開始されました | RBC Capital Mkts | Outperform |
| 2022-08-25 | 開始されました | Credit Suisse | Outperform |
| 2022-01-28 | 繰り返されました | Citigroup | Buy |
| 2020-01-08 | 開始されました | Wells Fargo | Overweight |
| 2020-01-07 | 開始されました | Citigroup | Buy |
| 2018-10-17 | 開始されました | Goldman | Buy |
| 2018-09-20 | 開始されました | Morgan Stanley | Equal-Weight |
| 2018-02-16 | ダウングレード | CL King | Buy → Neutral |
| 2017-07-13 | 開始されました | Wells Fargo | Outperform |
| 2017-06-28 | アップグレード | Deutsche Bank | Hold → Buy |
| 2017-01-18 | 開始されました | Deutsche Bank | Hold |
| 2016-10-13 | 開始されました | CL King | Buy |
| 2015-05-06 | 繰り返されました | Jefferies | Buy |
| 2009-12-18 | 開始されました | Maxim Group | Buy |
| 2009-11-06 | 開始されました | Jefferies & Co | Buy |
| 2009-07-17 | 開始されました | Soleil | Buy |
| 2007-09-26 | 開始されました | Banc of America Sec | Buy |
| 2007-02-23 | ダウングレード | Robert W. Baird | Outperform → Neutral |
すべてを表示
Bio Rad Laboratories Inc (BIO) 最新ニュース
Protein Engineering Market Is Going to Boom Rapidly With Top Key - openPR.com
Bio-Rad's Timing for Revenue Growth Recovery Remains Uncertain - Morningstar
United States Molecular Quality Controls Market to Reach CAGR - openPR.com
Dematic Automation Solution drives precision and productivity for Bio-Rad Singapore - mhdsupplychain.com.au
Is It Time To Reassess Bio-Rad Laboratories (BIO) After Multi Year Share Price Weakness - Yahoo Finance
Assessing Bio-Rad Laboratories (BIO) Valuation After Prolonged Share Price Weakness - Yahoo Finance
Bio-Rad Laboratories (BIO) Returns To Profitability With Diagnostics Rebound – Is The Turnaround Durable? - Yahoo Finance
Bio-Rad Laboratories Q4 2025 sales up 9% to USD 693.2M - Medical Buyer
Bio-Rad Laboratories, Inc. (NYSE:BIO) Q4 2025 earnings call transcript - MSN
Bio-Rad Laboratories, Inc. (NYSE:BIO) Q4 2025 Earnings Call Transcript - Insider Monkey
Bio-Rad Laboratories (NYSE:BIO) Lowered to "Hold" Rating by Wall Street Zen - MarketBeat
Beyond the Balance Sheet: What SWOT Reveals About Bio-Rad Labora - GuruFocus
Will Bio Rad Laboratories Inc. benefit from geopolitical trendsWeekly Profit Report & Low Risk Entry Point Tips - mfd.ru
Bio-Rad Q4 2025 slides reveal modest growth amid segment divergence and strategic shifts - Investing.com Nigeria
Bio-Rad Laboratories (NYSE:BIO.B) Shares Gap DownHere's What Happened - MarketBeat
Bio-Rad Laboratories Inc (BIO) Shares Down 11.17% on Feb 13 - GuruFocus
Oversold Conditions For Bio-Rad Laboratories (BIO) - Nasdaq
UBS Adjusts Price Target on Bio-Rad Laboratories to $335 From $350, Maintains Buy Rating - marketscreener.com
Bio-Rad Laboratories (BIO) Shares Cross Below 200 DMA - Nasdaq
Bio-Rad Laboratories (NYSE:BIO) Shares Gap Down After Earnings Miss - MarketBeat
Bio-Rad Laboratories, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Pinterest Posts Downbeat Results, Joins DraftKings, Toast, Expedia And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
S&P 500 Futures Drop In Premarket Trading; Pinterest, Bio-Rad Labs A Lag - 富途牛牛
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
BIO-RAD LABORATORIES, INC. SEC 10-K Report - TradingView
Bio-Rad (BIO) Reports Q4 Revenue Growth and Strategic Initiatives - GuruFocus
Bio-Rad Laboratories, Inc. $BIO Holdings Lifted by Envestnet Asset Management Inc. - MarketBeat
Bio-Rad outlines 2026 margin expansion and 0.5%-1.5% revenue growth guidance amid operational improvements - MSN
Bio-Rad Laboratories Q4 2025 Earnings Call Transcript - MarketBeat
Bio-Rad Laboratories Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: Bio-Rad Labs Q4 2025 misses EPS expectations By Investing.com - Investing.com South Africa
Bio-Rad Laboratories (NYSE:BIO.B) Posts Quarterly Earnings Results - MarketBeat
Bio-Rad (BIO) Q4 2025 Earnings Call Transcript - AOL.com
Bio-Rad: Q4 Earnings Snapshot - KVUE
BIO: 2025 results met guidance with diagnostics growth, ddPCR momentum, and cautious 2026 outlook - TradingView
BIO: 2025 saw resilient revenue and cash flow, with diagnostics growth and ddPCR momentum offsetting margin pressures - TradingView
Earnings call transcript: Bio-Rad Labs Q4 2025 misses EPS expectations - Investing.com India
Bio-Rad: Fourth Quarter Financial Highlights - Bitget
Bio-Rad Laboratories (BIO) Q4 Earnings Miss Estimates - Yahoo Finance
Bio-Rad Laboratories Swings To Q4 Profit - Nasdaq
Bio-Rad shares tumble as Q4 earnings miss expectations By Investing.com - Investing.com Australia
Bio-Rad Laboratories Posts Mixed Q4 2025 Financial Results - TipRanks
Bio-Rad shares tumble as Q4 earnings miss expectations - Investing.com UK
Earnings Flash (BIO) Bio-Rad Laboratories, Inc. Reports Q4 Revenue $693.2M, vs. FactSet Est of $688.8M - marketscreener.com
Bio-Rad Laboratories (NYSE:BIO) Announces Quarterly Earnings Results - MarketBeat
Is Bio Rad Laboratories Inc. stock risky to hold now2025 Analyst Calls & Verified Momentum Watchlists - mfd.ru
Bio-Rad Reports Fourth-Quarter and Full-Year 2025 Financial Results - Business Wire
Bio-Rad earnings on deck as estimates drift lower ahead of report - Investing.com South Africa
Bio-Rad earnings on deck as estimates drift lower ahead of report By Investing.com - Investing.com Nigeria
Is Bio Rad Laboratories Inc.’s ROE strong enough2025 Volatility Report & Capital Efficiency Focused Ideas - mfd.ru
Bio-Rad Laboratories Inc (BIO) Q4 2025 Earnings Call Highlights: Navigating Growth and Challenges By GuruFocus - Investing.com Canada
Bio Rad Laboratories Inc (BIO) 財務データ
収益
当期純利益
現金流量
EPS
1.13%
大文字化:
|
ボリューム (24 時間):